Neurovalens Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $18.5M

  • Investors
  • 19

Neurovalens General Information

Description

Developer of non-invasive neurostimulation products designed to treat global health epidemics. The company's medical device technology offers transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus to allow for alterations in autonomic function, circadian regulation and neuro-metabolic influence, enabling healthcare providers to provide drug-free options and improve patients' health outcomes.

Contact Information

Website
www.neurovalens.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor The Warehouse
  • 7 James Street South, County Antrim
  • Belfast BT2 8DN
  • Northern Ireland, United Kingdom
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Electronics (B2C)
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences
Corporate Office
  • 4th Floor The Warehouse
  • 7 James Street South, County Antrim
  • Belfast BT2 8DN
  • Northern Ireland, United Kingdom

Neurovalens Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurovalens Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
19. Later Stage VC 19-Aug-2025 $18.5M Completed Generating Revenue
18. Accelerator/Incubator 04-Jun-2024 Completed Generating Revenue
17. Later Stage VC (Series B) Cancelled Generating Revenue
16. Later Stage VC 08-Apr-2024 Completed Generating Revenue
15. Accelerator/Incubator 26-Mar-2024 Completed Generating Revenue
14. Accelerator/Incubator 01-Jun-2022 Completed Generating Revenue
13. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
12. Grant 02-Dec-2021 Completed Generating Revenue
11. Later Stage VC 29-Jun-2021 $1.45M $16.8M Completed Generating Revenue
10. Later Stage VC 20-Jul-2020 $6.37M $15.3M Completed Generating Revenue
To view Neurovalens’s complete valuation and funding history, request access »

Neurovalens Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A2 Preferred Ordinary
A2 Preferred Ordinary
A2 Preferred Ordinary
Ordinary
A Preferred
Ordinary
Preferred Ordinary
Preferred Ordinary
Preferred Ordinary 480,236 $0.000001 $1.48 $1.48 1x $1.48 1.65%
Ordinary 194,598 $0.000001 $1.48 $1.48 1x $1.48 0.67%
To view Neurovalens’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Neurovalens Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of non-invasive neurostimulation products designed to treat global health epidemics. The company's medical dev
Therapeutic Devices
Belfast, United Kingdom
29 As of 2026

Belfast, United Kingdom
 

Farum, Denmark
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurovalens Competitors (4)

One of Neurovalens’s 4 competitors is Cumulus (UK), a Venture Capital-Backed company based in Belfast, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cumulus (UK) Venture Capital-Backed Belfast, United Kingdom
MagVenture Corporation Farum, Denmark
Muse (Monitoring Equipment) Venture Capital-Backed Toronto, Canada
eNeura Venture Capital-Backed West Palm Beach, FL
To view Neurovalens’s complete competitors history, request access »

Neurovalens Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Neurovalens Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260115456-A1 Systems, devices and methods for treating post-infection symptoms of covid-19 using vestibular nerve stimulation Pending 31-Mar-2022
US-20250186772-A1 Devices and methods for treatment of anxiety- and stress-related disorders using vestibular nerve stimulation Pending 19-Mar-2020
US-12576271-B2 Systems, devices and methods for anxiety treatment using vestibular nerve stimulation Active 19-Mar-2020
US-20210290958-A1 Systems, devices and methods for anxiety treatment using vestibular nerve stimulation Active 19-Mar-2020
US-20260295250-A1 Systems, devices and methods for anxiety treatment using vestibular nerve stimulation Pending 19-Mar-2020 A61N1/36025
To view Neurovalens’s complete patent history, request access »

Neurovalens Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurovalens Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innovation Ulster University Minority
Northern Ireland Investment Fund Lender/Debt Provider Minority
Texas Medical Center Venture Capital Minority
Enterprise Hub - Royal Academy of Engineering Accelerator/Incubator
MedTech Innovator Accelerator/Incubator
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial

Neurovalens FAQs

  • When was Neurovalens founded?

    Neurovalens was founded in 2013.

  • Where is Neurovalens headquartered?

    Neurovalens is headquartered in Belfast, United Kingdom.

  • What is the size of Neurovalens?

    Neurovalens has 29 total employees.

  • What industry is Neurovalens in?

    Neurovalens’s primary industry is Therapeutic Devices.

  • Is Neurovalens a private or public company?

    Neurovalens is a Private company.

  • What is the current valuation of Neurovalens?

    The current valuation of Neurovalens is .

  • What is Neurovalens’s current revenue?

    The current revenue for Neurovalens is .

  • How much funding has Neurovalens raised over time?

    Neurovalens has raised $38.5M.

  • Who are Neurovalens’s investors?

    Innovation Ulster, Northern Ireland Investment Fund, Texas Medical Center, Enterprise Hub - Royal Academy of Engineering, and MedTech Innovator are 5 of 19 investors who have invested in Neurovalens.

  • Who are Neurovalens’s competitors?

    Cumulus (UK), MagVenture, Muse (Monitoring Equipment), and eNeura are competitors of Neurovalens.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process